CSL Ltd CMXHF:OTCQX

*Data is delayed | Exchange | USD
Last | 03/27/24 EDT
184.35UNCH (UNCH)
52 week range
144.81 - 207.67
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close184.35
  • 52 Week High207.67
  • 52 Week High Date06/13/23
  • 52 Week Low144.81
  • 52 Week Low Date10/25/23

Key Stats

  • Market Cap88,417.65M
  • Shares Out483.09M
  • 10 Day Average Volume263.88
  • Dividend2.16
  • Dividend Yield1.17%
  • Beta-
  • YTD % Change-5.46

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close184.35
  • 52 Week High207.67
  • 52 Week High Date06/13/23
  • 52 Week Low144.81
  • 52 Week Low Date10/25/23
  • Market Cap88,417.65M
  • Shares Out483.09M
  • 10 Day Average Volume263.88
  • Dividend2.16
  • Dividend Yield1.17%
  • Beta-
  • YTD % Change-5.46

RATIOS/PROFITABILITY

  • EPS (TTM)5.12
  • P/E (TTM)36.00
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date03/11/2024
  • Div Amount1.7989
  • Split Date-
  • Split Factor-

Latest On CSL Ltd

 

Profile

MORE
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides...
Brian McNamee
Non-Executive Independent Chairman of the Board
Paul Mckenzie
Chief Executive Officer, Managing Director, Executive Director
Joy Linton
Chief Financial Officer
William Mezzanotte M.D.
Executive Vice President, Head Research & Development and Chief Medical Officer
Mark Hill
Executive Vice President, Chief Digital Information Officer
Address
45 Poplar Road,, Parkville
Melbourne, VIC
3052
Australia